Comparative Pharmacology
Head-to-head clinical analysis: DEXILANT SOLUTAB versus ESOMEPRAZOLE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXILANT SOLUTAB versus ESOMEPRAZOLE SODIUM.
DEXILANT SOLUTAB vs ESOMEPRAZOLE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Proton pump inhibitor that irreversibly inhibits the H+/K+-ATPase enzyme system (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
30 mg orally once daily for 4-8 weeks; for non-erosive GERD, 30 mg orally once daily for 4 weeks; for erosive esophagitis, 60 mg orally once daily for up to 8 weeks; for maintenance of healed EE and relief of heartburn, 30 mg orally once daily. Administer without regard to food; dissolve tablet in water.
20-40 mg IV once daily for up to 10 days; oral: 20-40 mg once daily for 4-8 weeks for erosive esophagitis, 20 mg once daily for gastroesophageal reflux disease.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours; however, the pharmacodynamic half-life (duration of acid suppression) is prolonged due to accumulation in parietal cell canaliculi.
Terminal elimination half-life is approximately 1–1.5 hours in healthy individuals; clinical context: longer half-life (~2–3 hours) in slow CYP2C19 metabolizers, but acid suppression lasts longer due to irreversible binding to H+/K+-ATPase.
Renal (approx. 53% as metabolites, <2% as unchanged drug), biliary/fecal (approx. 47%).
Primarily hepatic metabolism (~80%) via CYP2C19 and CYP3A4; renal excretion of inactive metabolites accounts for ~80% of an oral dose, with ~20% excreted in feces via bile.
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor